Nektar Therapeutics (NASDAQ:NKTR) has been given a consensus recommendation of “Hold” by the eighteen analysts that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $37.00.
A number of equities research analysts recently commented on NKTR shares. Mizuho lowered shares of Nektar Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $79.00 to $21.00 in a report on Friday, August 9th. Zacks Investment Research lowered shares of Nektar Therapeutics from a “buy” rating to a “hold” rating and set a $34.00 price objective on the stock. in a report on Wednesday, July 31st. Jefferies Financial Group lowered shares of Nektar Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $59.00 to $23.00 in a report on Friday, August 9th. BidaskClub lowered shares of Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 16th. Finally, BMO Capital Markets dropped their price objective on shares of Nektar Therapeutics from $75.00 to $41.00 and set an “outperform” rating on the stock in a report on Friday, August 9th.
In other Nektar Therapeutics news, SVP Jillian B. Thomsen sold 1,809 shares of Nektar Therapeutics stock in a transaction on Friday, August 16th. The shares were sold at an average price of $18.15, for a total value of $32,833.35. Following the sale, the senior vice president now directly owns 92,668 shares in the company, valued at approximately $1,681,924.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Gil M. Labrucherie sold 25,000 shares of Nektar Therapeutics stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $15.83, for a total transaction of $395,750.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 173,535 shares of company stock worth $3,588,768. 4.02% of the stock is currently owned by company insiders.
NKTR traded up $0.46 during mid-day trading on Monday, hitting $17.73. The stock had a trading volume of 2,026,151 shares, compared to its average volume of 2,359,194. The stock’s fifty day simple moving average is $18.25 and its 200-day simple moving average is $27.66. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.09 and a quick ratio of 13.97. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of 4.69 and a beta of 2.65. Nektar Therapeutics has a 1-year low of $15.64 and a 1-year high of $48.44.
Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.17. Nektar Therapeutics had a negative net margin of 354.90% and a negative return on equity of 25.25%. The company had revenue of $23.32 million for the quarter, compared to analyst estimates of $26.65 million. During the same period last year, the business posted $5.33 earnings per share. The business’s revenue for the quarter was down 97.9% compared to the same quarter last year. As a group, research analysts expect that Nektar Therapeutics will post -2.85 earnings per share for the current fiscal year.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Featured Article: Current Ratio
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.